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Introduction: Glioblastoma (GBM) is the most common primary adult brain tumour with a median 
overall survival (OS) of 12-15 months. Molecular characterization of multiple immuno-oncology 
targets in GBM may help target novel immunotherapeutic strategies.  We used NanoString GeoMx® 
Digital Spatial Profiling (DSP) to assess multiple immuno-oncology protein targets in methylated 
versus unmethylated Glioblastoma IDH-wildtype.  
Methods: NanoString GeoMx® DSP technology uses multiple primary antibodies conjugated to 
indexing DNA oligos with a UV photocleavable linker. Tissue regions of interest (ROI) are selected 
with bound fluorescent antibodies, oligos are released via a UV-mediated linker and quantitated. We 
used DSP multiplex analysis of 31 immuno-oncology proteins and controls (CD4, CD14, CD68, CD8A, 
B7.H3, PD.L1, CD19, FoxP3, CD44, STAT3.phospho.Y705, CD45, Pan.Cytokeratin, MS4A1.CD20, 
CD45RO, PD1, CD3, Beta.2.Microglobulin, VISTA, Bcl.2, GZMB, PTEN, Beta.Catenin, CD56, Ki.67, 
STAT3, AKT, P.AKT, S6, Histone H3, IgG Rabbit Control, Mouse IgG Control) from ROIs in a cohort 
of 10 Glioblastomas IDH-wildtype (5 methylated, 5 unmethylated). An nCounter platform allowed 
quantitative comparisons of antibodies between ROIs in MGMT methylated and unmethylated tumours. 
Mean protein expression counts between methylated and unmethylated GBM were compared using 
technical and biological replicates.  
Results: The analysis showed 10/27 immuno-oncology target proteins were significantly increased in 
methylated versus unmethylated Glioblastoma IDH-wildtype tumour core (false discovery rate FDR 
<0.1 by Benjamini-Hochberg Procedure).  
Conclusions: NanoString GeoMx® DSP was used to analyse multiple immuno-oncology protein target 
expression in methylated versus unmethylated glioblastoma IDH-wildtype. In this small study there 
was a statistical increase in CD4, CD14, CD68, CD8A, B7-H3, PDL-1, CD19, FoxP3, CD44 and 
STAT3 protein expression in methylated versus unmethylated GBM tumour core, however this requires 
larger cohort validation. Advanced multiplex immuno-oncological biomarker analysis may be useful in 
identifying biomarkers for novel immunotherapeutic agents in GBMs. 
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Glioblastoma (GBM), the most common primary malignancy in adults has an annual incidence of 3.2 
per 100,000 [1]. Despite advances in surgical resection, chemotherapy and radiotherapy, GBM has a 
very poor prognosis [2]. Immune checkpoint inhibitors (ICIs) have shown efficacy in several cancers, 
including, and in particular, melanoma, head and neck cancer, renal cell carcinoma, non-small cell 
lung cancer and colorectal cancer [3-7]. ICIs, such as nivolumab and pembrolizumab, act to increase 
the immune response to an individual tumour by blocking the PD-1/PD-L1 interaction between host 
and tumour which may in part inhibit a T-cell mediated immune reaction and allow the tumour to 
evade the normal protective immune response [8]. Several clinical trials are underway to investigate 
the use of ICIs to enhance the immune response in GBM [9]. In particular CheckMate -143, a 
randomized Phase 3 clinical trial evaluating the efficacy and safety of PD-1 inhibitor nivolumab 
Opdivo in patients with first recurrence of glioblastoma multiforme (GBM), did not meet its primary 
endpoint of improved overall survival over bevacizumab monotherapy highlighting the need for more 
detailed analysis of immune-oncology biomarkers within GBM in order to better target novel immune 
therapeutics [10, 11].  Previous work in a cohort of 135 GBMs detected PD-L1 gene expression and 
Tumour Infiltrating Lymphocytes (TILs) in the majority of GBM cases suggesting potential utility of 
ICIs, although PD-L1 expression and TILs density was shown to be unrelated to GBM outcome and 
methylation status was not well defined [12].  
 
Protein expression in Formalin-fixed, paraffin-embedded (FFPE) tissue is conventionally measured by 
immunohistochemistry or immunofluorescence on a small number of proteins. By contrast, novel 
NanoString Digital Spatial Profiling (DSP) technology allows highly- multiplexed and spatially- 
resolved analysis of protein or RNA targets in multiple of Regions of Interest (ROIs) in FFPE tissue. 
With the theoretical ability to determine up to 800 protein targets on one FFPE section down to single-
cell resolution, multiple analytes, including immune targets, can be measured simultaneously using an 
optical-barcode based platform [13]. Furthermore, this technology enables multiple ROIs to be 
analysed, increasing the likelihood of identifying and locating variations in targets across the tissue due 
to intra-tumour heterogeneity [14].  
 
We used NanoString GeoMx® Digital Spatial Profiling (DSP) technology in 10 cases of glioblastoma 
IDH-wildtype [15] to quantify 27 immuno-oncology protein targets between ROIs in MGMT 
methylated and unmethylated tumours, additionally comparing tumour core and invasive margin 
regions. 
 
Materials and Methods 
 
DSP (see Figure 1) was undertaken using a cocktail of primary antibodies (NanoString GeoMx® Digital 
Spatial Profiling [DSP] technology immune panel Table 1) each with a unique, UV photocleavable 
indexing oligo. The tissue slide was placed on the stage of an inverted microscope. A custom gasket 
was then clamped onto the slide, allowing the tissue to be submerged in 1.5 mL of buffer solution. The 
microcapillary tip was connected to a syringe pump primed with buffer solution, allowing for accurate 
aspiration of small volumes (<10 µL). Under the microscope, wide field fluorescence imaging was 
performed with epi-illumination from a visible LED light engine. The ROI was then located using 
fluorescence imaging. A 20x image corresponded to 650µm x 650µm of tissue area using a 
Complementary Metal Oxide Semiconductor (CMOS) camera. The composite 20x images provided a 
high-resolution image of the ROI. The ROIs were then selected based on the fluorescence information 
and sequentially processed by the microscope automation. 
The steps performed for each ROI by the microscope automation were as follows: First, the 
microcapillary tip was washed by dispensing clean buffer out of the capillary and into a wash station. 
Next, the tissue slide was bulk washed by exchanging the buffer solution on the slide via the inlet and 
outlet wash ports on the gasket clamp. The microcapillary tip was then moved into position directly 
over the ROI with 50 µm from the tissue. The local region of tissue around the ROI was washed by 
dispensing 100 µL of buffer solution from the microcapillary. Then, the area of tissue within the ROI 
was selectively illuminated with UV light to release the indexing oligos. UV LED light was collimated 
to be reflected from the Digital Mirror Device (DMD) surface into the microscope objective and focused 
at the sample tissue.  Each micro mirror unit in the DMD corresponded to ~1µm2 area of sample and 
reflects the UV light in a controlled pattern based on the ROI selection in the image. Following each 
UV illumination cycle, the eluent was collected from the local region via microcapillary aspiration and 
transferred to an individual well of a microtiter plate/strip tube. Once all ROIs were processed, indexing 
oligos were hybridized to NanoString GeoMx® Digital Spatial Profiling (DSP) technology’s optical 




Full ethical approval from Brain Tumour Bank South West (REC: 11/WA/0016) was obtained for this 
study. In total, 10 glioblastoma IDH-wildtype cases (5 MGMT methylated and 5 MGMT 
unmethylated), were selected from patients diagnosed between 2012-2013.  MGMT methylation status 
had been previously determined by the Bristol Genetics Laboratory by use of the pyrosequencing assay 
described in Dunn et al. (2009) with optimised cut-offs: ≥12% methylated and ≤11% unmethylated 
(CpG sites 72-83) [16]. All slides were reviewed by a certified neuropathologist (KMK) to confirm the 
diagnosis. For each specimen, one 4‐μm‐thick FFPE section was cut from a single representative block 
and collected on adhesive glass slides.  Each of the 5 slides contained an adjacent MGMT methylated 
and unmethylated GBM section. Samples were classified as margin (30% in cellularity of tumour cells 
compared to background reactive neuroglial tissue) and solid tumour core (80% in cellularity of 
tumour cells compared to background reactive neuroglial tissue), in order to make clear distinction 
between the infiltrating edge and solid centre of the tumour.  
 
ROI selection  
 
The sections (see Figure 2) were stained with the visualization markers CD3 (red), GFAP (green) and 
DNA (blue) to assist with the selection of ROIs.  Six ROIs per section were selected by aligning 
fluorescent images with H&E images with ROIs pre-determined by a certified neuropathologist (KMK).  
Blood vessel and necrosis were kept to a minimum in the selected ROI. 
Each slide contained the following ROIs; denoted by white square (Figure 2): ROIs 1-3 (tumour core-
MGMT unmethylated), ROIs 4-6 (tumour margin-MGMT unmethylated), ROIs 7-9 (tumour core-




DSP enables detection of multiplexed proteins from the surface of FFPE tissue and protein quantitation 
from a defined ROI.  The cocktail of 31 antibodies (including controls) was applied to each FFPE 
unstained section.  Each antibody was conjugated to an indexing oligo by a UV-cleavable linker.  Upon 
highly controlled UV exposure of individual ROIs by a programmable micromirror device, the oligos 
were released by photocleavage and could be removed using a microcapillary tip into a microtiter plate 
[13].  Following each UV cycle, the oligos were subsequently hybridised to NanoString GeoMx® 
Digital Spatial Profiling (DSP) technology’s ‘barcodes’ and can be processed by quantitative detection 
using the nCounter analysis system providing digital counts [17] (Figure 1).  The digital counts 
produced corresponded to the abundance of each targeted protein in the ROI. 
 
Data Quality Control  
 
nCounter Assays included a set of 6 positive and 6 negative hybridisation control probes, Positive (POS) 
and Negative (NEG) A-F, respectively, to monitor hybridization efficiency, prep-station purification 
and imaging.  POS control targets were built into the Code Set reagent and thus reflected systematic 
variability between the assays.  
POS control performance was determined by the linearity of counts versus protein tag set concentration.  
Protein tag concentrations in the hybridization for protein tag positive control targets ranged from 
128fM (POS_A) to 0.125fM (POS_F) in a 4-fold titration. The expected correlation of POS control 
counts to protein tag target concentration was R2>0.95. 
Three data normalization systems were determined:   
 
1.1. Positive protein tag normalization (ERCC normalization): Data was normalized using the 
geometric mean of the protein tag positive control in each sample. For optimal results, 
normalization factors ranged between 0.7 and 1.7 for all assays (approximately 1.0 is optimal 
normalization factor). 
1.2. Housekeeper normalization: S6 Ribosomal Protein and Histone 3 were included in the antibody 
panel as housekeeper proteins. 
1.3. Signal:noise normalization: Mouse IgG1 and Rabbit IgG isotype controls were included in the 
antibody panel to assess the signal to noise ratio. 
 





Four ROIs (three in one sample, one in another sample) were excluded due to low housekeeping gene 
count (Histone H3 <1000). Housekeeping normalization factors were calculated by dividing the 
geometric mean of Histone H3 and Ribosomal S6 of individual ROI by the mean of all ROIs. The raw 
count was divided by the normalization factor. The normalized data was log2 transformed for variance 
stabilization.  
 
Comparing methylation status 
To compare the expression of genes between methylation status, the log2 normalized count was fit by 
the following linear mixed effect model:Log2 normalized count ~ methylation + (patient: methylation) 
Methylation is the fixed main effect that assesses the overall difference. The random interaction effect 
between patient and methylation in the parentheses allows the effect of methylation to vary among 
patients. The model is fit with the R package lmerTest. Log2 fold change was estimated and the p-
value was inferred using Satterthwaite’s degrees of freedom method provided in lmerTest. The 




The mean normalised count values for all 27 immune protein targets ranged from 6.47 to 19.26 (see 
Table 1: Mean (SD) log 2 housekeeping normalised values by location (core versus margin) and MGMT 
status). Overall, there was no statistical difference in counts between tumour core and tumour margin 
in either MGMT methylated or MGMT unmethylated IDH wildtype-GBM cases (Table 1). However, 
there was a statistically significant increase in CD4, CD14, CD68, CD8A, B7-H3, PDL-1, CD19, 
FoxP3, CD44 and STAT3 protein expression in methylated versus unmethylated GBM tumour core 
(see Table 2).  In the following mean [SD] are reported.  
 
Immune cell biomarker counts (Table 1) 
We observed comparatively low counts of CD45 pan-leukocyte marker (MGMT unmethylated tumour 
core mean normalised value [MGMTuc] = 7.93 [0.83], MGMT methylated tumour core mean 
normalised value [MGMTmc] = 9.19 [1.00]), and CD45RO isoform (MGMTuc 7.48 [0.50], MGMTmc 
8.29 [0.81]) which is in keeping with low immune infiltration irrespective of MGMT methylation status 
within GBM-IDH wildtype. The mean normalised count values of T lymphocyte marker CD3 are low 
(MGMTuc 8.04 [1.02], MGMTmc 8.90 [0.61]) and T helper cell marker CD4 (MGMTuc 9.58 [1.01], 
MGMTmc 11.22 [0.65]), which may indicate very low levels of T-cells and T helper cells respectively.   
Both B cell markers CD20 (MGMTuc 6.47 [0.53], MGMTmc 7.26 [0.63]) and CD19 (MGMTuc 6.66 
[0.63], MGMTmc 7.77 [0.74]) are reduced which also may indicate a very low number of B-
lymphocytes within cases. Mean normalised values for cytotoxic T-cell marker CD8A (MGMTuc 6.90 
[0.66], MGMTmc 8.30 [0.78]) may indicate low levels of cytotoxic T-cells. By comparison, GZMB 
(the protease granzyme B values = MGMTuc 10.27 [0.60], MGMTmc 10.65 [0.47]) shows elevated 
values. GZMB is a serine protease commonly found in the granules of cytotoxic T-cells and NK cells, 
and although difficult to be certain, the mild increased values may represent a difference in NK cells. 
We observed comparatively low normalised mean values of PD-1 (MGMTuc 7.43 [0.44], MGMTmc 
8.08 [0.73]) in keeping with overall comparatively low T-cell associated proteins in our cohort. 
 
Immune checkpoint and cancer biomarker counts (Table 2) : 
Table 2 shows p-values for MGMT comparison in tumour core (column 2) and margin (column 3) 
and for comparing core against margin in methylated (column 4) and in unmethylated (column 5). 
Overall there was a statistically significant difference between methylated and unmethylated tumour 
cores, but not tumour margins.  GeoMx DSP shows 10/27 immuno-oncology target proteins were 
significantly increased in methylated versus unmethylated Glioblastoma IDH-wildtype tumour core 
but not margin (false discovery rate (FDR) <0.1, by Benjamini-Hochberg Procedure). In particular, 
there was a statistically significant increase in CD4, CD14, CD68, CD8A, B7-H3, PDL-1, CD19, 
FoxP3, CD44 and STAT3 protein expression in methylated versus unmethylated GBM tumour core 
(see Table 2). There was no statistically significant difference in PD-1, VISTA, CD45, CD45RO, 
CD3, CD20, GZMB, STAT3.phospho.Y705, Beta-2-microglobulin, CD56, Beta-catenin, AKT, P-
AKT, PTEN, Bcl-2, Pan-Cytokeratin and Ki67 protein expression. 
 
In particular, in our cohort, checkpoint biomarker PD-L1 is statistically increased in MGMT methylated 
tumour cores compared with unmethylated tumour cores of GBMs (p=0.025) (see Table 2). The 
checkpoint molecule B7-H3 (CD276) is statistically increased in MGMT methylated tumour cores 
compared with unmethylated tumour cores of GBMs (p=0.023); MGMT methylated tumour core 
counts: 14.07 [1.02] compared to MGMT unmethylated GBM (tumour core: 12.35 [0.87]).  V-domain 
Immunoglobulin suppressor of T-cell activation VISTA is homologous to PD-L1 and a suppressor of 
T-cell activation, synergising with PD-1. By contrast VISTA is not statistically increased in MGMT 
methylated tumour cores compared with unmethylated tumour cores of GBMs (p=0.153); MGMT 
methylated tumour core (11.94 [0.70]), MGMT unmethylated tumour core (11.42 [ 0.77]) although 




In this paper we used NanoString GeoMx® Digital Spatial Profiling (DSP) technology to analyse 
multiple immune-oncology targets in methylated against unmethylated IDH-wildtype GBM tumours. 
NanoString GeoMx® Digital Spatial Profiling (DSP) technology has the theoretical ability to analyse 
a potential of 800 protein targets, therefore allowing: in-depth analysis of panels of tissue-based 
prognostic and predictive biomarkers, in-depth monitoring of response to therapies, and more rapid 
identification of targets of disease. The small sample of this technology feasibility study requires further 
validation of results in larger cohorts. 
 
Immune infiltration 
The mean log 2 housekeeping normalised values by location and MGMT status for all 27 immune 
protein targets ranged from 6.47 to 19.26 in our study (Table 1). NanoString GeoMx® Digital Spatial 
Profiling (DSP) technology has been tested in several studies reporting its robustness, sensitivity and 
reproducibility [18, 19, 20]. However, one potential disadvantage we identified using the technique 
was the lack of ability to draw direct comparisons between count values and immune cell numbers 
within samples because it is not possible to visualise cells and also there was a complex normalisation 
process and no standardised normalised tables were available for comparison. For example, the mean 
normalised values of CD3 (MGMTuc 8.04 [1.02], MGMTmc 8.90 [0.61]) and CD4 (MGMTuc 9.58 
[1.01], MGMTmc 11.22 [0.65]) may indicate very low levels of T-cells and T helper cells 
respectively within the tumours (see Table 2). In turn, both CD20 (MGMTuc 6.47 [0.53], MGMTmc 
7.26 [0.63]) and CD19 (MGMTuc 6.66 [0.63], MGMTmc 7.77 [0.74]) may indicate a low number of 
B lymphocytes. Mean normalised values for CD8A (MGMTuc 6.90 [0.66], MGMTmc 8.30 [0.78]) 
may indicate low levels of cytotoxic T-cells in the specimens studied, however, by comparison, 
GZMB (the protease granzyme B values = MGMTuc 10.27 [0.60], MGMTmc 10.65 [0.47]) showed 
comparatively elevated values. GZMB is a serine protease commonly found in the granules of 
cytotoxic T-cells and NK cells, and although difficult to be certain, it raises the possibility of 
increased NK cells within these specimens.  These findings however are in keeping with previous 
work in malignant gliomas suggesting that B-cells and the subtypes of T-cells are found in these 
tumours to varying degrees, with particularly low numbers of B-cells and CD4 helper T-cells [21]. 
Here, we observed comparatively low values for CD45RO (MGMTuc 7.48 [0.50], MGMTmc 8.29 
[0.81]) and CD45 (MGMTuc 7.93 [0.83], MGMTmc 9.19 [1.00]), which is in keeping with low 
immune infiltration irrespective of MGMT methylation status. Previous work has also suggested 
sparse-to-moderate density of TILs in 85 of 117 (72.6%) glioblastoma IDH-wildtype specimens 
(CD3+ 78/117, 66.7%; CD8+ 52/117, 44.4%; CD20+ 27/117, 23.1%) [12]. Furthermore, another 
study has shown TILs were enriched in glioblastomas of the mesenchymal class [22]. Yang et al.  
have reported that an increased immune infiltrate of CD8+ cytotoxic T-cells predicts improved long-
term survival in patients with glioblastoma [23], however this has not been replicated in many other 
studies. In our study, CD8 was not found to be increased in methylated compared to unmethylated 
tumour cores, however this study did not directly compare CD8 expression with patient survival. 
 
A direct lineage of CD4+ T-cells, T-regulatory cells are CD3+ CD4+ T-cells. T-regulatory cells 
suppress the response of self-reactive T-cells and down-regulate anti-tumour immunity. T-regs express 
the unique transcriptional repressor protein FOXP3 [24]. We observed a statistically significant 
difference in FOXP3 (p=0.03) between MGMT methylated and unmethylated tumour core, although 
overall counts are low (MGMTuc 7.02 [0.51], MGMTmc 7.94 [0.73]).  In a recent study of 186 
glioblastoma IDH-wildtype patients, consecutively treated with radiochemotherapy, the presence of 
FoxP3+ cells was associated with a better overall survival (P=0.04; HR: 0.62 [95%CI: 0.4-0.98]) [25], 
although other studies have shown that FoxP3+ infiltrate is associated with tumour recurrence [26]. 
Additionally, in a study by Fecci et al. it has been shown that absolute counts of both CD4+ T-cells and 
CD4+ CD25+ FOXP3+ CD45RO+ T-cells (i.e. T-regs) are reduced in patients with malignant glioma 
yet there is an increased fraction of the CD4+ compartment [27]. In another cohort of 135 gliomas 
including 52 glioblastomas regardless of pathological type, the median survival was 43 months [(95% 
confidence interval [CI], 26.9-Not Available months) in patients whose tumours stained negatively for 
FoxP3. In contrast, the median survival duration was 19.2 months (95% CI, 13.8-34.0 months) in 
patients whose tumours contained FoxP3+ T-regs (P < 0.001). It must be noted that this finding did not 
account for the confounding influence of tumour grade on survival. In this cohort patients with higher 
grade gliomas, who have shorter overall survival were more likely to have greater T-regs infiltration 
than patients with lower grade gliomas.  However, when the group performed univariate Cox 
proportional hazards analysis within glioma pathological subtypes, the percentage of cells that stained 
positive for FoxP3 did not seem to correlate with survival duration [28].  The degree of variability in 
the available literature on the impact of T-regulatory cells on OS of glioma patients, alongside the 




PD-L1 on glioblastoma cells interacts with PD-1 normally expressed on the surface of T-cells and this 
interaction may suppress T-cell activation.  In our cohort, PD-L1 expression is statistically increased in 
MGMT methylated tumour cores compared with unmethylated tumour cores of GBMs (p=0.025).  
Checkmate 143 also showed evidence of increased PD-L1 expression in a cohort 27/40 (68%) 
glioblastoma raising the possibility of PD-L1 inhibitor (nivolumab) use in clinical practice [10]. 
However, preliminary results published in a World Federation of Neuro-oncology Society (WFNOS) 
Meeting 2017 abstract, demonstrated a failure of PD-I inhibitor nivolumab to prolong overall survival 
of patients with recurrent glioblastoma, and this arm of the trial was prematurely closed [11]. One 
explanation for this lack of efficacy of nivolumab could be the lack of immune T cells within GBM in 
line with observed comparatively low normalised mean count values of PD-1 (MGMTuc 7.43 [0.44], 
MGMTmc 8.08 [0.73]) and in keeping with overall comparatively low T-cell associated proteins in our 
cohort, compared with PD-L1 (MGMTuc 11.50 ([0.57], MGMTmc 10.62 [0.58]). 
 
In addition, we observed higher overall mean normalised values of the checkpoint molecule B7-H3 
(CD276) irrespective of methylation status; MGMT methylated (tumour core: 14.07 [1.02], MGMT 
methylated tumour margin: 12.70 [0.94]) compared to MGMT unmethylated GBM (tumour core: 12.35 
[0.87], tumour margin: 12.52 [1.44]). We also noted a statistical increase of B7-H3 in MGMT 
methylated tumour core B7-H3 (CD276) against MGMT unmethylated tumour core (p=0.023). A 
similar expression pattern has recently been reported by a study (n=994) by Wang et al, who 
demonstrated B7-H3 upregulation in high-grade glioma hence lower overall survival [29]. B7-H3 
(CD276), which belongs to the B7 superfamily, has been shown to co-stimulate the proliferation of 
CD4+ and CD8+ T-cells, enhance the induction of cytotoxic T-cells and stimulate interferon gamma 
production [30]. In comparison to PD-1 and CTLA-4 checkpoints, the mechanism of B7-H3 (CD276) 
in suppressing tumour development still remains unclear [31]. Considering the conclusions drawn by 
Wang et al. and the emerging evidence from this small sample study, B7-H3 may be a potential 
therapeutic target that requires further investigation.  
 
V-domain Immunoglobulin suppressor of T-cell activation (VISTA), which is homologous to PD-L1, 
is a suppressor of T-cell activation, synergising with PD-1 [32, 33].  In addition, VISTA has also been 
shown to activate T-regs [34].  In our study, VISTA mean normalised counts were on the higher end of 
the normalised values’ range in both MGMT methylated and unmethylated GBM-IDH wildtype 
however there was no significant difference between groups: MGMT methylated tumour core 11.94 
[0.70], MGMT unmethylated tumour core 11.42 [0.77]. 
 
Although in our small study there was a statistically significant increase in CD4, CD14, CD68, CD8A, 
B7-H3, PDL-1, CD19, FoxP3, CD44 and STAT3 protein expression in methylated versus unmethylated 
GBM tumour core (see Table 2), we need to be cautions with these results due to the small sample size 




The small size of our cohort limits interpretation. In this study the four main sources of variation in 
using DSP are nCounter quantification, ROI background, ROI size and ROI cellularity [20]. Section-
to-section proximity and alignment may lead to small fluctuations in raw, normalized and relative 
nCounter data. In addition, section-to section variability may lead to decreased reproducibility of 
counts. Antibody cocktail lot variation may affect raw and positive protein tag normalization (ERCC 
normalization) nCounter counts. According to protocol, antibody cocktails are prepared fresh (i.e. 
weekly) which may lead to additional variation. In addition, pipetting variability and lot age can lead 
to differences in overall nCounter counts that can be corrected by Housekeeper normalization. 
Another disadvantage of DSP technology is that it only permits targeted discovery and a selection of 
targets is required to be included in the cocktail of antibodies, rather than ‘pure discovery’ [35]. Other 
than quantifying immune protein targets, this multiplex platform does not inform the mechanistic 
nature, properties and function of the complex cellular and molecular pathways that take place in the 
ROI as these occur in space and time. NanoString GeoMx® Digital Spatial Profiling (DSP) technology 
produces high dimensional multiplex data, which can complicate the normalisation process and calls 




In our experience careful consideration of the experimental design and normalisation process, with 
simultaneous in-depth understanding of DSP normalisation may optimise results.  In this small study 
there was a statistical increase in CD4, CD14, CD68, CD8A, B7-H3, PDL-1, CD19, FoxP3, CD44 and 
STAT3 protein expression in methylated versus unmethylated GBM tumour core, however this requires 
larger cohort validation. Advanced multiplex immuno-oncological predictive biomarker analysis may 






Figures, tables and legends 
 
Figure 1: Digital Spatial Profiling workflow. Morphology markers (GFAP, DAPI and CD3) plus a 
high-plex oligo-labelled antibody cocktail was first applied to the section. Regions of Interest (ROIs) 
were then selected for high-plex profiling using visible wavelength low-plex imaging to establish the 
tumour ‘geography’. Ultraviolet was used to release the oligo tags at the selected ROIs. The released 
tags were stored in a microtiter plate, which was then indexed and hybridized to barcodes. Up to 1 
million data points per ROI were digitally counted and this data was analysed with nSolver™Advanced 







Figure 2: (a) Photomicrographs of selected cases of glioblastoma (1-5). Each slide had a total of 12 
regions of interest (ROIs) selected; denoted by white square: ROI 1-3 (tumour -MGMT unmethylated), 
ROI 4-6 (margin-MGMT unmethylated), ROI 7-9 (tumour MGMT methylated), ROI 10-12 (margin 
MGMT unmethylated); (b) Close-up of regions of interest 1-12 selected on slide 1. The sections were 
stained with the visualization markers CD3 (red), GFAP (green), DNA (blue). ERCC normalized data 

















Table 1:  Mean (SD) log 2 housekeeping normalised values by location and MGMT status 
 
 Tumour Core  Tumour Margin 
 Methylated Unmethylated 
 
 Methylated Unmethylated 
Immuno-oncology targets  
and controls 
Mean (SD) Mean (SD)  Mean (SD) Mean (SD)  
      
CD4 11.22 (0.65) 9.58   (1.01)  10.16 (0.84) 9.68   (0.99) 
CD14 12.58 (1.61) 9.47 (1.46)  10.79 (1.07) 9.75 (1.31) 
CD68 12.97 (1.00) 11.14 (0.80)  12.32 (1.14) 11.67 (1.29) 
CD8A 8.30   (0.78) 6.90   (0.66)  8.06   (0.82) 7.70   (0.68) 
B7.H3 14.07 (1.02) 12.35 (0.87)  12.70 (0.94) 12.52 (1.44) 
PD.L1 11.50 (0.57) 10.62 (0.58)  11.47 (0.51) 11.65 (0.77) 
CD19 7.77   (0.74) 6.66   (0.63)  7.47   (0.37)  7.67   (0.87) 
FoxP3 7.94   (0.73) 7.02  (0.51)  7.75  (0.58) 7.88  (0.76) 
CD44 15.58 (1.24) 13.30 (1.60)  13.51 (1.49) 14.80 (2.61) 
STAT3.phospho.Y705. 9.41 (0.61) 8.64 (0.53)  8.52 (0.51) 9.06  (1.03) 
CD45 9.19 (1.00) 7.93 (0.83)  8.25 (0.83) 8.83 (1.44)  
Pan.Cytokeratin 9.11 (0.67) 8.43 (0.31)  8.92 (0.30) 9.35 (0.82) 
MS4A1.CD20. 7.26 (0.63) 6.47 (0.53)  7.15 (0.65) 7.50 (0.69) 
CD45RO 8.29 (0.81) 7.48 (0.50)  7.88 (0.39) 8.28 (0.92)  
S6 13.64 (0.30) 13.21 (0.39)  13.60 (0.32) 13.27 (0.46) 
PD1 8.08 (0.73) 7.43  (0.44)  7.47 (0.72) 7.87 (0.79) 
CD3 8.90 (0.61) 8.04 (1.02)  9.28 (0.70) 9.17 (1.00)  
Beta.2.Microglobulin 13.80 (1.12) 12.91 (0.53)  13.78 (0.69) 13.33 (1.02) 
VISTA 11.94 (0.70) 11.42 (0.77)  11.80 (0.45) 12.13 (1.59) 
Bcl-2 10.22 (0.84) 9.70 (0.50)  9.93 (0.32) 10.51 (1.12) 
GZMB 10.65 (0.47) 10.27 (0.60)  10.68 (0.68) 10.73 (0.46) 
PTEN 11.29 (1.11) 10.56 (1.08)  11.13 (0.59) 11.99 (1.57) 
Beta.Catenin 16.19 (0.66) 16.61 (0.51)  16.53 (0.52) 17.65 (0.72) 
CD56 18.40 (0.98) 17.73 (1.37)  19.26 (0.91) 19.15 (1.33) 
Ki.67 11.72 (1.76) 10.81 (1.27)  10.83 (0.99) 9.96 (1.49) 
STAT3 12.85 (1.44) 13.24 (0.87)  12.95 (0.83) 13.32 (0.89) 
AKT 14.57 (0.68) 14.55 (0.59)  15.06 (0.56) 14.82 (1.00) 













Table 2: p-values for MGMT comparison in tumour core (column 2) and margin (column 3) and 
for comparing core against margin in methylated (column 4) and in unmethylated (column 5) 
 
Immuno-oncology 
















CD4 0.005 0.452 0.050 0.452 
CD14 0.006 0.246 0.117 0.246 
CD68 0.007 0.416 0.316 0.416 
CD8A 0.011 0.383 0.617 0.383 
B7.H3 0.023 0.793 0.087 0.793 
PD.L1 0.025 0.639 0.875 0.639 
CD19 0.028 0.614 0.406 0.614 
FoxP3 0.030 0.722 0.577 0.722 
CD44 0.032 0.451 0.068 0.451 
STAT3.phospho.Y705
. 
0.034 0.396 *0.048 0.396 
CD45 *0.041 0.358 0.125 0.358 
Pan.Cytokeratin *0.048 0.370 0.617 0.370 
MS4A1.CD20. 0.053 0.347 0.738 0.347 
CD45RO 0.093 0.438 0.379 0.438 
S6 0.100 0.218 0.928 0.218 
PD1 0.121 0.390 0.205 0.390 
CD3 0.144 0.830 0.259 0.830 
Beta.2.Microglobulin 0.147 0.423 0.981 0.423 
VISTA 0.153 0.663 0.624 0.663 
Bcl.2 0.230 0.376 0.499 0.376 
GZMB 0.274 0.317 0.155 0.317 
PTEN 0.292 0.239 0.790 0.239 
Beta.Catenin 0.296 *0.025 0.473 *0.025 
CD56 0.357 0.860 0.105 0.860 
Ki.67 0.378 0.279 0.358 0.279 
STAT3 0.634 0.619 0.841 0.619 
AKT 0.946 0.644 0.207 0.644 
P.AKT 0.978 0.353 0.505 0.353 
*bold*: values statistically significant after Benjamini-Hochberg adjustment for False Discovery Rate 
at 0.1 
*: values statistically significant if unadjusted but not statistically significant after Benjamini-Hochberg 
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